

April 30, 2025

To The Manager, Listing Department National Stock Exchange of India Limited Plot no. C/1 G Block, Bandra-Kurla Complex, Bandra (East), Mumbai- 400 051 Symbol: BLISSGVS	To The General Manager, Listing Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400 001 Scrip Code: 506197
---	--

Dear Sir/Madam,

Subject: Initial Disclosure pursuant to SEBI Circular SEBI/HO/DDHS/DDHSRACPOD1/P/CIR/2023/172 dated October 19, 2023, to be made by entities identified as Large Corporate

Dear Sir/Madam,

We would like to inform you that our Company "Bliss GVS Pharma Limited" does **NOT** fall under the category of "Large Corporate" as per the applicability criteria mentioned under the SEBI Circular SEBI/HO/DDHS/DDHSRACPOD1/P/CIR/2023/172 dated October 19, 2023 read with SEBI Circular SEBI/HO/DDHS/P/CIR/2021/613 dated August 10, 2021, as updated as on April 13, 2022, with respect to fundraising by issuance of Debt Securities by Large Corporates.

Further, we are enclosing herewith **Annexure-A** as required under the aforesaid circular.

Kindly take the same on record.

Thanking you.

For **Bliss GVS Pharma Limited**

Aditi Bhatt
Company Secretary

Regd. Office : 102, Hyde Park, Saki Vihar Road, Andheri (East), Mumbai - 400 072, INDIA.

TEL. : (+91) (22) 42160000/ 28505387 • FAX. : (+91) (22) 28563930,

Email : info@blissgvs.com • Website : www.blissgvs.com • CIN - L24230MH1984PLC034771

Factory :

Plot No. 10, 11 & 12, Survey No. 38/1, Dewan Udyog Nagar, Aliyali Village, Tal. & Dist. Palghar - 401 404.

Tel. (+91) (02525) 252713 • Fax : (+91) (02525) 255257. • Email : factory@blissgvs.com

ANNEXURE A

Format of Initial Disclosure to be made by an entity identified as a Large Corporate

Sr. No.	Particulars	Details
1.	Name of the Company	Bliss GVS Pharma Limited
2.	CIN	L24230MH1984PLC034771
3.	Outstanding borrowing of company as on 31st March/ 31st December , as applicable (in Rs. cr)	47.59 Crores
4.	Highest Credit Rating during the previous financial year along with name of the Credit Rating Agency.	CRISIL BBB +/- Stable
5.	Name of Stock Exchange in which the fine shall be paid, in case of shortfall in the required borrowing under the framework.	NA

We confirm that we are not a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/DDHSRACPOD1/P/CIR/2023/172 dated October 19, 2023.

For **Bliss GVS Pharma Limited**

Deepak Sawant
Chief Financial Officer
Contact Details-022-42160000

Aditi Bhatt
Company Secretary
Contact Details-022-42160000

Date: April 30, 2025